Petosemtamab targets both EGFR as well as leucine-rich repeat-containing G-protein coupled receptor 5 (LGR-5), which is known to be upregulated in cancer and is also pro-oncogenic by encouraging cell proliferation and reducing apoptosis. The gene discussed is EGFR; the disease is cancer.